Azurity Archives
News and events as they happenGeorge Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US
An innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, that can deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, as demonstrated in clinical trials, with an established safety profile
Azurity Pharmaceuticals announces the FDA Approval of XIFYRM™ (meloxicam injection) for the Management of Moderate-to-Severe Pain in Adults
FOR IMMEDIATE RELEASE Woburn, MA — June 10, 2025 — Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRMTM (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
MEDIA ALERT: WOBURN, MA, March 14, 2025 – Azurity Pharmaceuticals (“Azurity”) announced today the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.
AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF
AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII
MEDIA ALERT: WOBURN, Mass. December 11, 2024 – Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency…